CEO in Coloplast Kristian Villumsen is disappointed over FDA's decision to ban the company's transvaginal synthetic mesh product although the prohibition only has marginal impact on Coloplast's revenue. However, analyst calls the case "bad news" for the company.
Log in to read our articles
Welcome to MedWatch. A part of our content is exclusive and reserved for our users.